HOLDINGS has completed a draw on its Equity Line of Credit to support the commercial launch of Arbli Oral Suspension, while ...

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers ...

Scienture shares originally traded higher on Tuesday but have since reversed and began trading lower after the company ...

Arbli TM is the first and only FDA approved ready-to-use oral liquid losartan in the U.S. market. Arbli TM is a novel proprietary formulation of losartan, a proven therapy for treating ...

Scienture (SCNX) announces the U.S. Food and Drug Administration, FDA, has approved SCN-102, one of the products being developed by Scienture, ...

Scienture Holdings, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its liquid formulation of losartan, branded as ArbliTM (losartan potassium) Oral Suspension ...

Read below for more. Scienture is advancing a liquid formulation of the popular blood pressure drug losartan, for which the FDA has a target action date of March 17. The asset, dubbed SCN-102, is ...

Losartan (Cozaar) is a generic drug that is prescribed for certain conditions, including high blood pressure. Losartan comes as an oral tablet and belongs to the angiotensin II receptor blocker ...

In a remarkable development, researchers have successfully turned light into a supersolid for the first time, paving the way for new insights into the unusual quantum states of matter. This ...

Why We Love It: For a liquid foundation that gives full coverage and lasts all day, please turn your attention to Chanel. This luxurious foundation provides a flawless matte finish that conceals ...